Contemporary vaccine development relies less on empirical methods of vaccine construction, and now employs a powerful array of precise engineering strategies to construct immunogenic live vaccines. In this review, we will survey various engineering techniques used to create attenuated vaccines, with an emphasis on recent advances and insights. We will further explore the adaptation of attenuated strains to create multivalent vaccine platforms for immunization against multiple unrelated pathogens. These carrier vaccines are engineered to deliver sufficient levels of protective antigens to appropriate lymphoid inductive sites to elicit both carrier-specific and foreign antigen-specific immunity. Although many of these technologies were originally developed for use in Salmonella vaccines, application of the essential logic of these approaches will be extended to development of other enteric vaccines where possible. A central theme driving our discussion will stress that the ultimate success of an engineered vaccine rests on achieving the proper balance between attenuation and immunogenicity. Achieving this balance will avoid over-activation of inflammatory responses, which results in unacceptable reactogenicity, but will retain sufficient metabolic fitness to enable the live vaccine to reach deep tissue inductive sites and trigger protective immunity. The breadth of examples presented herein will clearly demonstrate that genetic engineering offers the potential for rapidly propelling vaccine development forward into novel applications and therapies which will significantly expand the role of vaccines in public health.
Details
- The Delicate Balance in Genetically Engineering Live Vaccines
- Galen, James E. (Author)
- Curtiss, Roy (Author)
- ASU Biodesign Center Immunotherapy, Vaccines and Virotherapy (Contributor)
- Biodesign Institute (Contributor)
-
Digital object identifier: 10.1016/j.vaccine.2013.12.026
-
Identifier TypeInternational standard serial numberIdentifier Value0264-410X
-
NOTICE: this is the author's version of a work that was accepted for publication. Changes may have been made to this work since it was submitted for publication. The definitive version can be viewed at http://dx.doi.org/10.1016/j.vaccine.2013.12.026
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Galen, James E., & Curtiss, Roy, III (2014). The delicate balance in genetically engineering live vaccines. VACCINE, 32(35), 4376-4385. http://dx.doi.org/10.1016/j.vaccine.2013.12.026